"
Team:Paris Bettencourt/YonatanTest
From 2013.igem.org
| Line 89: | Line 89: | ||
<div class="bkgr"> | <div class="bkgr"> | ||
<h2>Background</h2> | <h2>Background</h2> | ||
| - | <p> | + | <p>SirA is an essential gene in latent tuberculosis infections </p> |
</div> | </div> | ||
<div class="aims"> | <div class="aims"> | ||
<h2>Aims</h2> | <h2>Aims</h2> | ||
| - | <p> | + | <p>To perform an drug screen targeted at the sirA gene from mycobacteria</p> |
</div> | </div> | ||
</div> | </div> | ||
| Line 100: | Line 100: | ||
<h2>Results</h2> | <h2>Results</h2> | ||
<ul> | <ul> | ||
| - | + | <li>Produced an E. coli strain which relies upon mycobacterial sirA, fprA and fdxA genes to survive in M9 minimal media</li> | |
| - | + | <li>Demonstrated that E. coli can survive with mycobacterial sulfite reduction pathway with Flux Balance Analysis</li> | |
| - | + | <li>Located drug target sites on sirA as well as identified high structural similarity between cysI and sirA through structural anaylsis</li> | |
| + | </ul> | ||
</div> | </div> | ||
<div class="biocriks"> | <div class="biocriks"> | ||
| - | <center> <img width="95%" style="margin-top:30px" src="https://static.igem.org/mediawiki/2013/ | + | <center> <img width="95%" style="margin-top:30px" src="https://static.igem.org/mediawiki/2013/0/0e/PB_bb_target1.png"/><br></center> |
</div> | </div> | ||
| Line 112: | Line 113: | ||
<div class="mainfig"> | <div class="mainfig"> | ||
<center> <img width="100%" src="https://static.igem.org/mediawiki/2013/3/31/PB_fig_target1.png"/></center> | <center> <img width="100%" src="https://static.igem.org/mediawiki/2013/3/31/PB_fig_target1.png"/></center> | ||
| - | <p style="font-size:13px"> MycoSIR E. coli depend on our synthetic pathway for growth. E. coli strain BL21(DE3) was deleted for cysI and transformed with the three genes of the mycoSIR pathway expressed from IPTG-inducible T7 promoters (red). Wild-type (blue), uninduced (purple) and pathway-minus (gold) strains were used as controls. Both time course growth curves (A) and final ODs (B) reveal that the complete, induced pathway is | + | <p style="font-size:13px"> MycoSIR E. coli depend on our synthetic pathway for growth. E. coli strain BL21(DE3) was deleted for cysI and transformed with the three genes of the mycoSIR pathway expressed from IPTG-inducible T7 promoters (red). Wild-type (blue), uninduced (purple) and pathway-minus (gold) strains were used as controls. Both time course growth curves (A) and final ODs (B) reveal that the complete, induced pathway is required for growth |
</p> | </p> | ||
| Line 121: | Line 122: | ||
</div> | </div> | ||
| + | <div id="page"> | ||
| + | <h2><a href="https://2013.igem.org/Team:Paris_Bettencourt/Project/Infiltrate">Infiltrate</a></h2> | ||
| + | <div class="overbox"> | ||
| + | <div class="subbox1"> | ||
| + | <div class="bkgr"> | ||
| + | <h2>Background</h2> | ||
| + | <p>text </p> | ||
| + | </div> | ||
| + | <div class="aims"> | ||
| + | <h2>Aims</h2> | ||
| + | <p>text</p> | ||
| + | </div> | ||
| + | </div> | ||
| + | <div class="subbox2"> | ||
| + | <div class="results"> | ||
| + | <h2>Results</h2> | ||
| + | text | ||
| + | </div> | ||
| + | <div class="biocriks"> | ||
| + | <center> <img width="95%" style="margin-top:30px" src="https://static.igem.org/mediawiki/2013/5/55/PB_Bb_target.png"/><br></center> | ||
| + | |||
| + | </div> | ||
| + | </div> | ||
| + | <div class="mainfig"> | ||
| + | <center> <img width="100%" src="https://static.igem.org/mediawiki/2013/3/31/PB_fig_target1.png"/></center> | ||
| + | <p style="font-size:13px"> Figure caption | ||
| + | |||
| + | </p> | ||
| + | </div> | ||
| + | </div> | ||
| + | <div style="clear: both;"></div> | ||
| + | |||
| + | </div> | ||
Revision as of 21:49, 25 October 2013
Detect
Background
CRISPR/Cas systems generate site-specific double strand breaks and have recently been used for genome editing.
Aims
Building a genotype sensor based on CRISPR/Cas that reports existance of an antibiotic resistance gene.
Results
- Successfully cloned gRNA anti-KAN, crRNA anti-KAN, tracrRNA-Cas9 and pRecA-LacZ into Biobrick backbones and therefore generated four new BioBricks.
- Testing the new assembly standard for our cloning.
CRISPR anti-Kan plasmids target kanamycin resistant E. coli. WT (blue) and a kanamycin resistant strain (KanR, red) were co-transformed with a plasmid carrying the Cas9 construct, and a second plasmid carrying the anti-Kanamycin gRNA. WT was successfully transformed with one or both plasmids. KanR E. coli couldn’t be tranformed with both plasmids because of Cas9-induced cleavage of the chromosome specifically at the KanR cassette, with about 99% efficiency.
Target
Background
SirA is an essential gene in latent tuberculosis infections
Aims
To perform an drug screen targeted at the sirA gene from mycobacteria
Results
- Produced an E. coli strain which relies upon mycobacterial sirA, fprA and fdxA genes to survive in M9 minimal media
- Demonstrated that E. coli can survive with mycobacterial sulfite reduction pathway with Flux Balance Analysis
- Located drug target sites on sirA as well as identified high structural similarity between cysI and sirA through structural anaylsis
MycoSIR E. coli depend on our synthetic pathway for growth. E. coli strain BL21(DE3) was deleted for cysI and transformed with the three genes of the mycoSIR pathway expressed from IPTG-inducible T7 promoters (red). Wild-type (blue), uninduced (purple) and pathway-minus (gold) strains were used as controls. Both time course growth curves (A) and final ODs (B) reveal that the complete, induced pathway is required for growth
Infiltrate
Background
text
Aims
text
Results
textFigure caption
+33 1 44 41 25 22/25
team2013@igem-paris.org 
